Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676103 · ClinicalTrials.gov registry record · Phase 1
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease
A Phase 1 study, sponsored by New York Institute of Technology.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01676103 is a Phase 1 study that has completed, run by New York Institute of Technology. The registered enrollment target is 40 participants.
The verdict
NCT01676103, a Phase 1 study, has completed, sponsored by New York Institute of Technology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this experiment is: * Primary: To determine the effects of tyrosine supplementation on orthostatic hypotension in people with PD. * Secondary: To determine the effects of tyrosine supplementation in people with PD with autonomic insufficiency on HR, BP, and norepinephrine responses during acute exercise stress. Orthostatic hypotension and autonomic abnormalities are a common problem for individuals who suffer from PD, especially as it leads to lightheadedness and falling. For those affected, it can drastically reduce quality of life. It has been hypothesized that tyrosine may impact upon individuals suffering from PD. There is ample evidence in animal models that supports our theory; however there is no clinical evidence of the impact tyrosine supplementation may have in PD patients who suffer from orthostatic hypotension and blunted BP and HR responses. Positive findings that supplemental tyrosine increases BP and HR in people with PD during daily activities such as standing up from a chair and walking can lead to new therapies to improve Parkinsonian orthostatic hypotension. Hypothesis We will test the hypothesis that symptomatic individuals with PD on dopamine therapy who suffer from orthostatic hypotension and blunted HR and BP responses will improve after tyrosine supplementation.
Interventions
- DIETARY_SUPPLEMENT Tyrosine
- OTHER Placebo Comparator:Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676103
The ClinicalTrials.gov registry entry for NCT01676103 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Institute of Technology, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tyrosine is the first listed.
NCT01676103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676103 about?
NCT01676103 is a clinical study titled "The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease". The objective of this experiment is: * Primary: To determine the effects of tyrosine supplementation on orthostatic hypotension in people with PD. * Secondary: To determine the effects of tyrosine supplementation in people with PD with autonomic insufficiency on HR, BP, and norepinephrine responses...
What is the current status of trial NCT01676103?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01676103?
The interventions under investigation include: Tyrosine (DIETARY_SUPPLEMENT), Placebo Comparator:Sugar Pill (OTHER).
Who is sponsoring clinical trial NCT01676103?
This trial is sponsored by New York Institute of Technology, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.